As observed at the end of 4 weeks of the combined treatment, the concomitant administration of JD and BO restored UCP2 level, decreased levels of both NF-κB and oxidative stress despite JD (Figures 6c and d and Supplementary Figure S2), and led to a significant delay of stroke occurrence (Figure 6e). Here, UCP2 is linked to stroke disorder.